

**Per-reviewed publications by transfusion medicine fellows  
based on scholarly work done at Yale during their fellowship  
(2010-present)**

Cheng C, Tormey CA, Hendrickson JE. Limitations of a scoring model to predict thrombotic thrombocytopenic purpura. *Vox Sang* [Epub ahead of print]

Sidhu D, Snyder EL, Tormey CA. Two approaches to the clinical dilemma of treating TTP with therapeutic plasma exchange in patients with a history of anaphylactic reactions to plasma. *J Clin Apher* [Epub ahead of print]

Parker V, Tormey CA. The direct antiglobulin test: Indications, interpretation, and pitfalls. *Arch Pathol Lab Med* [Epub ahead of print]

Ryder AB, Hendrickson JE, Tormey CA. Chronic inflammatory autoimmune disorders are a risk factor for red blood cell alloimmunization. *Br J Haematol* 2016;174:483-5.

Hendrickson JE, Hendrickson ET, Gehrie EA, Sidhu D, Wallukat G, Schimke I, Tormey CA. Complex regional pain syndrome and dysautonomia in a 14-year-old girl responsive to therapeutic plasma exchange. *J Clin Apher* 2016;31:368-74.

Unold D, Tormey CA. Clinical applications of 4-factor prothrombin complex concentrate: A practical pathologist's perspective. *Arch Pathol Lab Med* 2015;139:1568-75.

Gehrie EA, Hendrickson JE, Tormey CA. Measuring the influence of blood component infusion rate on recipient vital signs. *Vox Sang* 2015;109:353-8.

Gehrie EA, Hendrickson JE, Tormey CA. Variation in vital signs resulting from blood component administration in adults. *Transfusion* 2015;55:1866-71.

Gehrie E, Tormey C. Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal. *Arch Pathol Lab Med* 2015;139:687-92.

Gehrie EA, Booth GS. Stem cell collection considerations for AL amyloidosis. *Conn Med* 2014;78:587-90.

Unni N, Peddinghaus M, Tormey CA, Stack G. Record fragmentation due to transfusion at multiple health care facilities: a risk factor for delayed hemolytic transfusion reactions. *Transfusion* 2014;54:98-103.

Gehrie EA, Tormey CA. The influence of clinical and biological factors on transfusion-associated non-ABO antigen alloimmunization: Responders, hyper-responders, and non-responders. *Transfus Med Hemother* 2014;41:420-9.

Gehrie EA, Tormey CA. The development and implementation of, and first years' experience with, a massive/emergency transfusion protocol (damage control hematology protocol) in a Veterans Affairs hospital. *Mil Med* 2014;179:1099-105.

Ryder AB, Zimring JC, Hendrickson JE. Factors influencing RBC alloimmunization: Lessons learned from murine models. *Transfus Med Hemother* 2014;41:406-19.

Maitta RW, Avery L, Champion M, Vaughn D, Baillargeon C, Lederer J, Snyder EL. How do we integrate transfusion medicine and tissue dispensing programs in an academic medical center: response to a changing regulatory environment. *Transfusion* 2012;52:1172-81.

Maitta RW, Choate J, Emre SH, Luczycki SM, Wu Y. Emergency ABO-incompatible liver transplant secondary to fulminant hepatic failure: outcome, role of TPE and review of the literature. *J Clin Apher* 2012;27:320-9.

Choate J, Snyder EL. The rise of cellular therapy. *Transfus Apher Sci* 2011;45:91-7.

Snyder E, Choate J. The emergence of cellular therapy: impact on transfusion medicine. *Transfusion* 2010;50:2301-9.

Tormey CA, Peddinghaus ME, Erickson M, King KE, Cushing MM, Bill J, Goodrich T, Snyder EL. Improved plasma removal efficiency for therapeutic plasma exchange using a new apheresis platform. *Transfusion* 2010;50:471-7.